Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a humanized antibody targeting the cell surface antigen cluster of differentiation 228 (CD228; melanotransferrin; MFI2; MELTF) that is conjugated, via a beta-glucuronidase-cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Following administration, the antibody moiety of anti-CD228/MMAE ADC SGN-CD228A targets and binds to CD228 on the surface of tumor cells. Following internalization of SGN-CD228A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CD228-expressing tumor cells. CD228, a cell-surfaced, glycosylphosphatidylinoitol (GPI)-anchored glycoprotein, belongs to the transferrin family of iron-binding proteins.

**Synonyms:** - Anti-CD228 Antibody-drug Conjugate SGN-CD228A - Anti-CD228-MMAE ADC SGN-CD228A - Anti-CD228/MMAE ADC SGN-CD228A - Anti-melanotransferrin ADC SGN-CD228A - SGN CD228A - SGN-CD228A - SGNCD228A